Tag: MorphoSys
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results...
– Topline data from the Phase 3 MANIFEST-2 study expected in early 2024
– Monjuvi® U.S. net product sales of US$ 25.3 million (€...
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation PharmaceuticalsInvestment is anchored by royalties on Janssen’s TremfyaPartnership also includes...